Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Apply
SPX-303
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step